Changes in invasive pneumococcal disease in the paediatric population in the second COVID-19 pandemic year
This study was funded by the Carlos III Health Institute of Madrid (ISCIII; PI17/00337) and the Catalan Agency for the Management of University Research Grants (AGAUR; grant numbers 2017/SGR 1342 and 2021/SGR 00742).
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:20.500.12328/3876 |
| Acceso en línea: | http://hdl.handle.net/20.500.12328/3876 https://dx.doi.org/10.3390/vaccines11101548 |
| Access Level: | acceso abierto |
| Palabra clave: | Impacte de la COVID-19 Malaltia pneumocòcica invasiva Vacuna antipneumocòcica conjugada 13-valent Mesures no farmacèutiques Impacto de la COVID-19 Enfermedad neumocócica invasiva Vacuna neumocócica conjugada de 13 valencias Medidas no farmacéuticas Impact of COVID-19 Invasive pneumococcal disease Pneumococcal 13-valent conjugate vaccine Non-pharmaceutical measures 61 |
| Sumario: | This study was funded by the Carlos III Health Institute of Madrid (ISCIII; PI17/00337) and the Catalan Agency for the Management of University Research Grants (AGAUR; grant numbers 2017/SGR 1342 and 2021/SGR 00742). |
|---|